| Code | Description | Claims | Beneficiaries | Total Paid |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,674 |
10,345 |
$920K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13,857 |
11,179 |
$696K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,828 |
2,235 |
$139K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,164 |
2,056 |
$129K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
975 |
739 |
$111K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,734 |
1,459 |
$98K |
| 99050 |
|
8,927 |
7,559 |
$68K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
837 |
798 |
$53K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
6,837 |
5,486 |
$49K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,472 |
1,972 |
$47K |
| 90670 |
|
1,697 |
1,544 |
$43K |
| 90677 |
|
332 |
303 |
$40K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
731 |
598 |
$38K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
381 |
348 |
$36K |
| 99381 |
|
609 |
432 |
$29K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
479 |
382 |
$29K |
| 90700 |
|
2,361 |
2,175 |
$27K |
| 90716 |
|
985 |
929 |
$26K |
| 87634 |
|
482 |
384 |
$24K |
| 90713 |
|
1,830 |
1,662 |
$23K |
| 87481 |
|
255 |
189 |
$20K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
822 |
670 |
$20K |
| 90680 |
|
1,024 |
919 |
$19K |
| 90707 |
|
994 |
941 |
$19K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
6,578 |
5,583 |
$19K |
| 90648 |
|
1,749 |
1,596 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,388 |
1,203 |
$16K |
| 99401 |
|
1,176 |
933 |
$16K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
465 |
438 |
$16K |
| 92551 |
|
1,807 |
1,657 |
$16K |
| 90633 |
|
1,133 |
1,080 |
$13K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
730 |
598 |
$12K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
173 |
166 |
$10K |
| 90744 |
|
946 |
809 |
$10K |
| 90686 |
|
904 |
836 |
$10K |
| 90651 |
|
175 |
162 |
$9K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
866 |
699 |
$9K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
233 |
174 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
700 |
537 |
$9K |
| 99072 |
|
2,302 |
1,729 |
$7K |
| 87807 |
|
560 |
474 |
$6K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
80 |
80 |
$6K |
| 87640 |
|
253 |
189 |
$5K |
| 87653 |
|
253 |
189 |
$5K |
| 99383 |
|
69 |
66 |
$5K |
| 99173 |
|
2,415 |
2,210 |
$5K |
| 90619 |
|
106 |
104 |
$5K |
| 90461 |
|
3,522 |
3,115 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
313 |
135 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
186 |
159 |
$3K |
| 87581 |
|
122 |
112 |
$3K |
| 87486 |
|
122 |
112 |
$3K |
| 99382 |
|
57 |
53 |
$3K |
| 90698 |
|
179 |
161 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
1,354 |
1,152 |
$2K |
| 87500 |
|
93 |
68 |
$2K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
40 |
37 |
$2K |
| 99386 |
|
17 |
14 |
$2K |
| 99188 |
|
98 |
93 |
$2K |
| 96160 |
|
898 |
802 |
$2K |
| 90734 |
|
83 |
74 |
$2K |
| 81002 |
|
558 |
458 |
$1K |
| 90715 |
|
75 |
72 |
$1K |
| 99385 |
|
14 |
13 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
303 |
263 |
$1K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
128 |
113 |
$844.04 |
| 83655 |
|
75 |
70 |
$775.08 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
103 |
86 |
$389.61 |
| 90685 |
|
32 |
30 |
$333.79 |
| 93000 |
|
26 |
24 |
$328.29 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
138 |
123 |
$274.00 |
| 90656 |
|
17 |
17 |
$210.05 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
146 |
121 |
$150.33 |
| A7015 |
Aerosol mask, used with dme nebulizer |
143 |
118 |
$129.16 |
| 99001 |
|
100 |
83 |
$22.08 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
95 |
79 |
$8.55 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
14 |
12 |
$8.13 |
| 94760 |
|
39 |
30 |
$6.56 |
| J7699 |
Noc drugs, inhalation solution administered through dme |
13 |
12 |
$3.75 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
81 |
62 |
$2.79 |